StreetInsider.com News Articles

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

The analyst comments "We initiate coverage of EQ with a Buy rating and a $9 PT. We believe lead asset EQ504, an oral AhR agonist, offers an attractive risk-reward profile in IBD, with a UC P1 trial set to initiate in 3Q26 and data expected in 1H27. EQ504 combines biologically validated mechanism, colon-targeted delivery to enhance safety, and once-daily oral convenience. EQ504 has the potential to break the current efficacy ceiling, supported by its pleiotropic biology, which overlaps with obefazimod’s

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

Piper Sandler Starts Equillium (EQ) at Overweight

Mon, 13 Jul 2026 04:02:18 -0400

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ: EQ) with a Overweight rating and a price target of $20.00.

The analyst comments: “We are initiating coverage on Equillium, Inc. (EQ) with an OW rating and $20 PT, where we believe EQ is significantly undervalued compared to competitors within the UC space. Notably, their lead asset is EQ504, an AhR modulator clinically validated by indigo naturalis and obefazimod yet instilled with potential for higher potency and differentiated colontargeted engagement for cleaner safety. Accordingly, we review this depth of data from 4 studies of AhR modulators and obefazimod which collectively rationalize

Piper Sandler Starts Equillium (EQ) at Overweight

Mon, 13 Jul 2026 04:02:18 -0400

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ: EQ) with a Overweight rating and a price target of $20.00.

Oppenheimer Reiterates Outperform Rating on Equillium (EQ)

Tue, 30 Jun 2026 06:42:54 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $7.00 price target on Equillium (NASDAQ: EQ).

The analyst commented: "We see last night's positive maintenance data reveal from Abivax in ulcerative colitis (UC) as supportive for EQ504. Obefazimod's (obe's) impressive efficacy in refractory Phase 3 subsets, as achieved through treatment continuation and/or dose escalation, adds validation for EQ's more potent immunomodulator as it enters UC clinical development. While we regarded malignancy concerns as triggered by ABVX's recent disclosure as obe-specific given cumulative AhR modulator experience, last night's more mature safety update should nonetheless assuage any investor worry here re EQ504. Reiterate

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Fri, 05 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26612123.html

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Fri, 05 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26612123.html

Form 4 Equillium, Inc. For: Jun 05 Filed by: Zedelmayer Christine

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611827.html

Form 4 Equillium, Inc. For: Jun 05 Filed by: Zedelmayer Christine

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611827.html

Form 4 Equillium, Inc. For: Jun 04 Filed by: Connelly Stephen

Fri, 05 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260605/26611820.html

Form 4 Equillium, Inc. For: Jun 04 Filed by: Connelly Stephen

Fri, 05 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260605/26611820.html

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Thu, 04 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260604/26606932.html

Form 144 Equillium, Inc. Filed by: Connelly Stephen

Thu, 04 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260604/26606932.html

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

The stock option has an exercise

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

The stock option has an exercise

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

The stock option has an exercise

Form 4 Equillium, Inc. For: May 28 Filed by: Tom Penny

Fri, 29 May 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260529/26576886.html

Form 4 Equillium, Inc. For: May 28 Filed by: Tom Penny

Fri, 29 May 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260529/26576886.html

Form 4 Equillium, Inc. For: May 28 Filed by: DEMSKI MARTHA J

Fri, 29 May 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260529/26576885.html

Form 4 Equillium, Inc. For: May 28 Filed by: DEMSKI MARTHA J

Fri, 29 May 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260529/26576885.html

Form 4 Equillium, Inc. For: May 28 Filed by: Pruzanski Mark

Fri, 29 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576882.html

Form 4 Equillium, Inc. For: May 28 Filed by: Pruzanski Mark

Fri, 29 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576882.html

Form 4 Equillium, Inc. For: May 28 Filed by: BRADBURY DANIEL

Fri, 29 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26576877.html

Form 4 Equillium, Inc. For: May 28 Filed by: BRADBURY DANIEL

Fri, 29 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26576877.html